All In Biotech

NDA 021515 · Bausch

Wellbutrin Xl

Bupropion Hydrochloride · Oral

Last checked: Nov 20, 2026Latest source record: Nov 5, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2003

Aug 28, 2003

Approved uses

2

Original approval plus efficacy supplements

Registered trials

440

96 Phase 3, 24 recruiting

FAERS reports

89,988

46,161 serious, 4,230 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS SUICIDALITY AND ANTIDEPRESSANT DRUGS Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials. These trials did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in subjects aged 65 and older [ see Warnings and Precautions (5.1) ]. In patients of all ages who are started on antidepressant therapy, monitor closely for worsening, and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber [ see Warnings and Precautions (5.1) ]. WARNING: SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning. • Increased risk of suicidal thinking and behavior in children, adolescents, and young adults taking...

What it is approved for

From the label in effect Feb 10, 2026.

Wellbutrin XL is an aminoketone antidepressant, indicated for: • treatment of major depressive disorder (MDD) ( 1.1 ) • prevention of seasonal affective disorder (SAD) ( 1.2 ) 1.1 Major Depressive Disorder (MDD) Wellbutrin XL ® (bupropion hydrochloride extended-release) tablets is indicated for the treatment of major depressive disorder (MDD), as defined by the Diagnostic and Statistical Manual (DSM). The efficacy of the immediate-release formulation of bupropion was established in two 4-week controlled inpatient trials and one 6-week controlled outpatient trial of adult patients with MDD. The efficacy of the sustained-release formulation of bupropion in the maintenance treatment of MDD was established in a long-term (up to 44 weeks), placebo-controlled trial in patients who had responded to bupropion in an 8-week study of acute treatment [ see Clinical Studies (14.1) ]. 1.2 Seasonal Affective Disorder (SAD) Wellbutrin XL is indicated for the prevention of seasonal major depressive episodes in patients with a diagnosis of seasonal affective disorder (SAD). The efficacy of bupropion hydrochloride extended-release tablets in the prevention of seasonal major depressive episodes was established in 3 placebo-controlled trials in adult outpatients with a history of MDD with an autumn-winter seasonal pattern as defined in the DSM [ see Clinical Studies (14.2) ].

Mechanism: The mechanism of action of bupropion is unknown, as is the case with other antidepressants. However, it is presumed that this action is mediated by noradrenergic and/or dopaminergic mechanisms. Bupropion is a relatively weak inhibitor of the neuronal uptake of norepinephrine and dopamine and does not inhibit monoamine oxidase or the reuptake of serotonin.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 12, 2006 Supplement 10 · Efficacy · priority review LabelLetter
  • Aug 28, 2003 Original approval · Type 3 - New Dosage Form LabelReviewLetter
2 products under this application
  • WELLBUTRIN XL · BUPROPION HYDROCHLORIDE 150MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB3
  • WELLBUTRIN XL · BUPROPION HYDROCHLORIDE 300MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB3

Clinical trials

Interventional ClinicalTrials.gov studies with "Bupropion" as an intervention, any sponsor and status, largest first.

All 440 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective8,670
  • nausea7,203
  • fatigue6,643
  • headache6,487
  • depression5,807
  • anxiety5,186
  • pain4,988
  • dizziness4,680
  • off label use4,354
  • insomnia4,118
  • diarrhoea3,370
  • rash3,205

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20043,898
20053,945
20063,762
20072,837
20082,449
20092,653
20102,917
20112,829
20123,352
20132,804
20143,128
20155,162
20165,804
20174,618
20184,468
20195,035
20204,644
20214,230
20224,604
20234,291
20244,912
20254,319
20263,326

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Wellbutrin XL (Bupropion HCl)

2024 spending

$81.9M

Beneficiaries

3,395

18,653 claims

Per beneficiary

$24,122

$74.76 per unit

View as table
YearSpending
2020$74,015,160
2021$75,767,020
2022$76,885,992
2023$77,459,753
2024$81,893,852

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,202 on PubMed

Sponsor: Bausch

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.